돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 1045583생성일: 2026년 10월 25일

Potassium Phosphate, Tribasic → 2-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-1-(piperidin-1-yl)ethanone

https://huagongshe.com/reaction/1045583

반응식

참여 물질

역할이름HCID투입량
반응물Potassium Phosphate, TribasicHCID 62657—
반응물L-ProlineHCID 145742—
반응물2-Chloro-1-piperidine-1-yl-ethanoneHCID 222312—
반응물1,2,3,4,5,6-Hexahydro-3,9-dimethylazepino[4,5-b]indoleHCID 68560092—
촉매Copper(1+) iodide; Copper(I) iodide; Cuprous iodide; Cuprous iodide (CuI)HCID 24350—
용매DimethylformamideHCID 6228—
생성물2-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-1-(piperidin-1-yl)ethanoneHCID 593682818.8%

반응 단계

The title compound was prepared by following general procedure 7. 3,9-Dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (100 mg, 0.47 mmol), was taken into DMF. CuI (9 mg, 0.046 mmol), L-proline (11 mg, 0.093 mmol), K3PO4 (198 mg, 0.93 mmol) were added to the solution and stirred for 10 min. at RT. 2-Chloro-1-(piperidin-1-yl)ethanone (91 mg, 0.56 mmol) was added dropwise. The reaction mixture was heated at 90° C. for 12 h. After completion of reaction, the reaction mixture was filtered through Celite. DMF was evaporated under reduced pressure and then extracted with ethyl acetate. The organic layer was dried over Na2SO4, and concentrated under reduced pressure to obtain 14 mg of 2-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-1-(piperidin-1-yl)ethanone as the TFA salt after purification by reverse-phase chromatography (C-18, 500 mm×50 mm, Mobile Phase A=0.05% TFA in water, B=0.05% TFA in acetonitrile, Gradient: 10% B to 80% B in 30 min., injection vol. 5 mL).

출처 및 근거

DOI10.6084/m9.figshare.5104873.v1
특허 번호US08569287B2
출처 데이터셋uspto-grants-2013_10
ORD IDord-bef30e39d7bf4bca91602a84eb6f0aa2
출처 메모uspto-grants-2013_10